GILD SEC Filings: 8-K, 10-Q, S-3 & 424B – Gilead Sciences

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 29, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 24, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 7, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Gilead Sciences Announces Third Quarter 2026 Financial Results and Raises Full-Year Guidance

Oct 29, 2026

8-K

Gilead Sciences Reports Second Quarter 2026 Financial Results and Strategic Updates

Aug 4, 2026

8-K

Gilead Sciences, Inc. Announces Issuance of $3 Billion in Senior Notes

May 20, 2026

8-K

Gilead Sciences Reports Q1 2026 Financial Results and Raises Full-Year Revenue Guidance

May 7, 2026

8-K

Gilead Sciences, Inc. Announces Results of 2026 Annual Meeting of Stockholders

May 4, 2026

8-K

Gilead Sciences Completes Acquisition of Arcellx

Apr 28, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

May 18, 2026

424B5

PENDING FIXED PRICE OFFERING | Bank: Barclays, BofA Securities, Citigroup

May 14, 2026

424B5

.00 | Offering amount: $750,000,000.00 | Bank: Barclays, BofA Securities, Citigroup, Goldman Sachs & Co. LLC, HSBC, J.P. Morgan, Mizuho, Morgan Stanley, RBC Capital Markets, SOCIETE GENERALE, TD Securities, US Bancorp, Wells Fargo Securities

Nov 15, 2024

424B5

PENDING OFFERING | Bank: Barclays, BofA Securities

Nov 13, 2024

424B5

Common Stock

Sep 11, 2023

424B5

Common Stock

Sep 7, 2023

Registrations

TYPE

HEADLINE

FILED AT

S-3ASR

August 2026 SHELF

Aug 6, 2026

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

May 14, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 7, 2026

SC TO-T/A

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

Apr 28, 2026

SC TO-T/A

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

Apr 17, 2026

SC TO-T/A

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

Apr 1, 2026

Proxies

TYPE

HEADLINE

FILED AT

N-PX

Form N-PX - Annual Report of proxy voting record of management investment companies

Aug 26, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 20, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 20, 2026

N-PX

Form N-PX - Annual Report of proxy voting record of management investment companies

Aug 29, 2025

PX14A6G

Form PX14A6G - Notice of exempt solicitation submitted by non-management

Apr 7, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 27, 2025

Ownerships

TYPE

HEADLINE

FILED AT

NEWCain Wettan Keeley M (Reporting)

Nov 9, 2026

SCHEDULE 13G

GILEAD SCIENCES, INC. (Filed by)

Nov 6, 2026

O'Day Daniel Patrick (Reporting)

Nov 6, 2026

144

Form 144 - Report of proposed sale of securities

Nov 6, 2026

13F-HR

Form 13F-HR - Quarterly report filed by institutional managers, Holdings

Nov 5, 2026

144

Form 144 - Report of proposed sale of securities

Nov 4, 2026

Other

TYPE

HEADLINE

FILED AT

CORRESP

Form CORRESP - Correspondence

Mar 11, 2024

LETTER

Form UPLOAD - SEC-generated letter

May 5, 2023

CORRESP

Form CORRESP - Correspondence

Apr 25, 2023

LETTER

Form UPLOAD - SEC-generated letter

Mar 29, 2023

CT ORDER

Form CT ORDER - Confidential treatment order

Feb 2, 2022

CORRESP

Form CORRESP - Correspondence

Oct 2, 2020

Gilead Sciences, Inc. GILD · SEC Filings